Virtual GMP Consulting

Ranbaxy, Wishful Thinking and the Fudge Factor

FDA Cites "Shadow" Heparin Manufacturing Plants in China

Dangerous Documents101: When a Shredder Isn't Enough, There's a Preventive Course

You Can't Duct Tape Quality: FDA Issues Consent Decree against Actavis Totowa

Engineers Nail QbD in Philadelphia

"Heparin Was an Industry Wake-Up Call": A Star Turn by CDER's Janet Woodcock

Pharma 483s Speaking the Language of QbD

Is Synthetic Heparin the Solution?